Immuron Limited (IMRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMRN POWR Grades
- IMRN scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.94% of US stocks.
- The strongest trend for IMRN is in Stability, which has been heading up over the past 156 days.
- IMRN ranks lowest in Growth; there it ranks in the 6th percentile.
IMRN Stock Summary
- IMRN has a market capitalization of $21,616,397 -- more than approximately just 4.32% of US stocks.
- The ratio of debt to operating expenses for Immuron Ltd is higher than it is for about only 0.48% of US stocks.
- With a year-over-year growth in debt of -100%, Immuron Ltd's debt growth rate surpasses only 0% of about US stocks.
- Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are HAPP, GIGM, SVVC, WAFU, and EDTK.
- Visit IMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.immuron.com.au.
IMRN Stock Price Chart Interactive Chart >
IMRN Price/Volume Stats
| Current price | $4.85 | 52-week high | $28.99 |
| Prev. close | $4.85 | 52-week low | $1.92 |
| Day low | $4.68 | Volume | 14,400 |
| Day high | $4.93 | Avg. volume | 55,066 |
| 50-day MA | $5.51 | Dividend yield | N/A |
| 200-day MA | $6.98 | Market Cap | 27.55M |
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
Latest IMRN News From Around the Web
Below are the latest news stories about Immuron Ltd that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Immuron (ASX:IMC) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual ConferenceMELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week. Details of the events are as follows: * H.C. Wainwright Virtual BioConnect Conference January 11 – 14, 2021: The company’s presentation will take place on Monday, January 11, 2021, at 6 a.m. US EST and will be available to all conference-registered institutional investors. A copy of the presentation will be available on Immuron’s website ... |
Immuron SARS-CoV-2 Research Agreement with Monash UniversityKey Points * Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. * A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of th... |
Immuron Receives AUD $358,280 R&D Tax Concession RefundMELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year. This release has been authorised by the directors of Immuron Limited.COMPANY CONTACT: Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 [email protected] About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceuti... |
Immuron Shares Resume Trade Following Circuit Breaker To Upside; Stock Pulling Back From Session High, Still Up 30%This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of … |
IMRN Price Returns
| 1-mo | 0.21% |
| 3-mo | -17.38% |
| 6-mo | -27.72% |
| 1-year | -43.87% |
| 3-year | -49.29% |
| 5-year | N/A |
| YTD | -23.86% |
| 2020 | 75.48% |
| 2019 | N/A |
| 2018 | 0.00% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching IMRN
Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...